Fly News Breaks for August 20, 2019
Aug 20, 2019 | 13:00 EDT
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating and $7 price target on Mersana Therapeutics, noting that the expansion cohort dosing of XMT-1536 at 36 mg/m, which was higher than anticipated, "offers significant breathing room, and should clear the air on the safety profile."
News For MRSN From the Last 2 Days
There are no results for your query MRSN